Natural HCV resistance is common in Italy and differently associated to genotypes
M.C. Sorbo(University of Rome Tor Vergata), Francesca Ceccherini‐Silberstein(University of Cologne), Miriam Lichtner(Sapienza University of Rome), Massimo Puoti(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Adriano Pellicelli(Carlo Forlanini Hospital), Giuliano Rizzardini, Elisabetta Teti(University of Rome Tor Vergata), Laura Ambra Nicolini(Ospedale Policlinico San Martino), Loredana Sarmati(University of Rome Tor Vergata), Bianca Bruzzone(Ospedale Policlinico San Martino), Vincenza Calvaruso(University of Palermo), Stefania Paolucci(Policlinico San Matteo Fondazione), M. Melis(University of Sassari), F. De Leonardis(University of Rome Tor Vergata), Simona Landonio(ASST Fatebenefratelli Sacco), Antonio Gasbarrini(Università Cattolica del Sacro Cuore), M. Aragri(University of Rome Tor Vergata), C. Pasquazzi(Azienda Ospedaliera Sant'Andrea), Sergio Babudieri(University of Sassari), Fausto Baldanti(University of Pavia), Ennio Polilli(Azienda USL di Pescara), Gloria Taliani(Sapienza University of Rome), M. Angélico, Chiara Masetti(NHS Blood and Transplant), Massimo Andreoni(University of Rome Tor Vergata), Dante Romagnoli(University of Modena and Reggio Emilia), Nicola Coppola(University of Campania "Luigi Vanvitelli"), Velia Chiara Di Maio(University of Rome Tor Vergata), A Pieri(Azienda USL di Pescara), Barbara Menzaghi(Ospedale di Circolo di Busto Arsizio), I. Lenci(University of Rome Tor Vergata), T. Ruggiero, Pietro Andreoné, Giustino Parruti(Azienda USL di Pescara), Valeria Micheli(ASST Fatebenefratelli Sacco), Alessandro Bertoli(University of Padua), Elisa Biliotti(Sapienza University of Rome), N. Iapadre(San Salvatore Hospital), Stefano Marenco(National Institutes of Health), Carlo Federico Perno(Centre International De Reference Chantal Biya), Antonio Craxı̀(University of Palermo), Martina Milana(University of Rome Tor Vergata), Laura Gianserra(Azienda Ospedaliera Sant'Andrea), Vincenzo Vullo(Policlinico Umberto I), Valeria Pace Palitti(Azienda USL di Pescara), C. Magni(ASST Fatebenefratelli Sacco), Massimo Siciliano(Università Cattolica del Sacro Cuore), Filomena Morisco, P. Cacciatore(Azienda USL di Pescara), Valeria Cento(Rostov State Medical University)
Cited by 1
Related Papers
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Commensal Clostridia: leading players in the maintenance of gut homeostasis
|Gut Pathogens|2013|753